Sarepta Therapeutics: Why The Newborn Screening Decision For DMD Matters More Than The Stock Move Suggests

2025-12-17 06:48:20 ET

Thesis

The big news yesterday is that the U.S. Department of Health and Human Services ((HHS)) has made the decision to add Duchenne muscular dystrophy (DMD) to the recommended newborn screening panel. Now I see this as being great news for Sarepta Therapeutics ( SRPT ) and much more impactful than the 3.5% stock bump we saw yesterday. You see, Sarepta's current DMD treatment options are preventative and need to be given before muscular damage has occurred. So now with the screening mandatory, Sapreta's treatment option will have far more use between that one- to four-year age range where they're effective. I also see this decision as having a big impact on payer reimbursement, as I'll explain. Since my previous coverage, the stock has been on an upward climb and has jumped about 46%. Back then, their late-stage ESSENCE trial failure was a massive setback. However, now with this latest news, I'm upgrading my call to a buy rating as I see more upside ahead for this stock heading into next earnings....

Read the full article on Seeking Alpha

For further details see: